Search research articles
Contact Us
Filters
Showing results (1-10 of 33) with videos related to
Page
of 4
Sort By:
Biomedicines
|
June 26, 2025
NK Cells in Health and Disease
Matthew D Blunt
Blood
|
March 21, 2024
Targeting CD161 in B-cell malignancies
Matthew D Blunt
International Journal of Immunogenetics
|
November 23, 2019
Activating killer cell immunoglobulin-like receptors: Detection, function and therapeutic use
Matthew D Blunt, Salim I Khakoo
Current Opinion in Pharmacology
|
April 10, 2012
Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia
Matthew D Blunt, Stephen G Ward
Blood
|
December 31, 2016
Releasing the brakes on BTK-targeting miRNA
Matthew D Blunt, Andrew J Steele
Frontiers in Immunology
|
August 10, 2012
Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: success, disappointment, and new opportunities
Matthew D Blunt, Stephen G Ward
Immunotherapy Advances
|
January 15, 2024
Harnessing natural killer cell effector function against cancer
Matthew D Blunt, Salim I Khakoo
Leukemia Research Reports
|
October 27, 2015
Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia
Matthew D Blunt, Andrew J Steele
Blood
|
June 25, 2016
To BH3 profile or not to BH3 profile
Matthew D Blunt, Andrew J Steele
Journal of Translational Genetics and Genomics
|
December 10, 2021
The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma
Frazer Warricker, Salim I Khakoo, Matthew D Blunt
Page
of 4
Search research articles
Search
Showing results (1-10 of 33) with videos related to
Sort By:
Page
of 4
Biomedicines
|
June 26, 2025
NK Cells in Health and Disease
Matthew D Blunt
Blood
|
March 21, 2024
Targeting CD161 in B-cell malignancies
Matthew D Blunt
International Journal of Immunogenetics
|
November 23, 2019
Activating killer cell immunoglobulin-like receptors: Detection, function and therapeutic use
Matthew D Blunt, Salim I Khakoo
Current Opinion in Pharmacology
|
April 10, 2012
Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia
Matthew D Blunt, Stephen G Ward
Blood
|
December 31, 2016
Releasing the brakes on BTK-targeting miRNA
Matthew D Blunt, Andrew J Steele
Frontiers in Immunology
|
August 10, 2012
Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: success, disappointment, and new opportunities
Matthew D Blunt, Stephen G Ward
Immunotherapy Advances
|
January 15, 2024
Harnessing natural killer cell effector function against cancer
Matthew D Blunt, Salim I Khakoo
Leukemia Research Reports
|
October 27, 2015
Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia
Matthew D Blunt, Andrew J Steele
Blood
|
June 25, 2016
To BH3 profile or not to BH3 profile
Matthew D Blunt, Andrew J Steele
Journal of Translational Genetics and Genomics
|
December 10, 2021
The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma
Frazer Warricker, Salim I Khakoo, Matthew D Blunt
Page
of 4